- Scinai will exhibit at the upcoming CPHI Barcelona event, showcasing its CDMO services
- The company expanded into the CDMO business earlier this year, operating under the banner Scinai Bioservices
- Scinai’s boutique end-to-end CDMO business division serves pharmaceutical, biotech, and alternative protein food tech companies with pilot and clinical process development and cGMP manufacturing
- Scinai intends to serve small biotech companies who require CDMO services with superior value compared to large, multinational CDMO companies
- Scinai will also exhibit at the upcoming BIO-Europe conference in Munich
Scinai Immunotherapeutics (NASDAQ: SCNI), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, will be showcasing its Contract Development and Manufacturing Organization (“CDMO”) services at CPHI Barcelona, a premier three-day event that brings together pharmaceutical professionals, industry leaders, and businesses to advance human health. The event is scheduled for October 24 to 26, 2023, at Fira Barcelona Gran Via, Spain (https://ibn.fm/veEp4).
The company has been allocated Booth 81HA11, where potential partners and clients of the company’s CDMO service will get to meet several members of Scinai’s executive leadership team. Registered attendees may also request one-on-one meetings through the CPHI partnering platform.
Earlier this year, Scinai announced its expansion into the CDMO business, now operating under the banner Scinai Bioservices (https://ibn.fm/uqyUC). A boutique end-to-end CDMO service, Scinai Bioservices serves pharmaceutical, biotech, and alternative protein food tech companies with pilot and clinical process development and manufacturing.
“We decided to leverage our state-of-the-art biologics pilot manufacturing plant by commencing a new CDMO services business unit. The need for CDMO services by small biotech companies is high and growing, and the current offerings by large, multinational CDMO companies are expensive and with limited available capacity,” Amir Reichman, Scinai’s CEO, said in an August 1 news release (https://ibn.fm/UQBJ6).
According to PwC’s 2022 Global CDMO Study of Pharmaceutical Operations, only 37% of the CDMOs studied offer end-to-end services, spanning development, drug substance manufacturing, and drug product manufacturing through to packaging (https://ibn.fm/RXEWW). This statistic suggests an unsaturated market and a massive opportunity for CDMOs, such as Scinai Bioservices, that can provide end-to-end services. In fact, in the report, PwC observes that “becoming one-stop-shop solution providers can strengthen [CDMOs’] market position.”
To thrive today, PwC believes CDMOs must become full-service providers for pharmaceutical companies to differentiate themselves from competitors. This is a consideration Scinai implemented when it expanded into the CDMO business.
Scinai Bioservices provides cGMP manufacturing services with manufacturing suites that include clean rooms for upstream fermentation, downstream purification, media and buffer preparations, automatic aseptic filling to vials and prefilled syringes (“PFSs”), and labeling and visual inspection. Moreover, the manufacturing site is designed to meet the U.S. Food and Drug Administration (“FDA”) and European Medicines Agency (“EMA”) GMP standards and has previously passed audits conducted by EMA and the Israeli Ministry of Health, according to Scinai’s website (https://ibn.fm/hNKul).
The division also offers technical research and development (“R&D”) and quality control (“QC”) laboratories, which support manufacturing process development and scale-up, analytical methods development, and in-process controls and product release testing. Client companies will also benefit from Scinai’s in-house expertise and deep pharma experience.
“Our site is a perfect match for a small biotech in that it is well equipped, staffed with highly trained personnel, and its business and quality processes are in place. We see quite a lot of demand for our services and are aggressively pursuing clients. If successful, this business unit could generate meaningful income in the relatively short term,” Reichman concluded.
For more information, visit the company’s website at www.Scinai.com.
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN